Back to search

Article

Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans

2025-07-28

Abstract excerpt

The new generation of incretin-based therapies are potent anti-obesity medications (AOMs) that offer the first non-surgical treatment for 936 million patients globally suffering from being overweight or obese[1]. However, clinical data suggest that incretin-mimetics could cause a disproportionate decrease in lean body mass (LBM) [2, 3], raising a concern for deterioration of skeletal muscle and acceleration of sar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c2d04ad1-fed3-56a1-bbc9-2a0b828e67d8
DOI
10.1101/2025.07.28.25332295
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humansDOI 10.1101/2025.07.28.25332295
Select a neighboring publication to make it the new centre.